JP6091811B2 - ピラゾール化合物及びその医薬用途 - Google Patents
ピラゾール化合物及びその医薬用途 Download PDFInfo
- Publication number
- JP6091811B2 JP6091811B2 JP2012190429A JP2012190429A JP6091811B2 JP 6091811 B2 JP6091811 B2 JP 6091811B2 JP 2012190429 A JP2012190429 A JP 2012190429A JP 2012190429 A JP2012190429 A JP 2012190429A JP 6091811 B2 JP6091811 B2 JP 6091811B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl group
- compound
- alkoxy
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(*)(C(F)(F)F)OCc1cc(Cl)cc(-c2cc(NC(C(C3)CNC3=O)=O)n[n]2-c2ccccc2)c1 Chemical compound CC(*)(C(F)(F)F)OCc1cc(Cl)cc(-c2cc(NC(C(C3)CNC3=O)=O)n[n]2-c2ccccc2)c1 0.000 description 9
- GZVHQYZRBCSHAI-VKHMYHEASA-N OC([C@@H](C1)CNC1=O)=O Chemical compound OC([C@@H](C1)CNC1=O)=O GZVHQYZRBCSHAI-VKHMYHEASA-N 0.000 description 2
- JAPMJSVZDUYFKL-UHFFFAOYSA-N C1C2C1CCC2 Chemical compound C1C2C1CCC2 JAPMJSVZDUYFKL-UHFFFAOYSA-N 0.000 description 1
- RTGUJFWBQLNZDR-UHFFFAOYSA-N CC(C(CN1)C(O)=O)C1=O Chemical compound CC(C(CN1)C(O)=O)C1=O RTGUJFWBQLNZDR-UHFFFAOYSA-N 0.000 description 1
- OYWLPGFTSRFJJK-IPFXWSOASA-N CC(C(CN1Cc(c(OC)c2)ccc2OC)C(N([C@H](Cc2ccccc2)CO2)C2=O)=O)C1=O Chemical compound CC(C(CN1Cc(c(OC)c2)ccc2OC)C(N([C@H](Cc2ccccc2)CO2)C2=O)=O)C1=O OYWLPGFTSRFJJK-IPFXWSOASA-N 0.000 description 1
- RLYAPKHVGSBBJN-UHFFFAOYSA-N CC(C(CN1Cc(ccc(OC)c2)c2OC)C(O)=O)C1=O Chemical compound CC(C(CN1Cc(ccc(OC)c2)c2OC)C(O)=O)C1=O RLYAPKHVGSBBJN-UHFFFAOYSA-N 0.000 description 1
- SYMOGWFEUPBHHR-LFUZPPSTSA-N CC(C(F)(F)F)(C=C)OCc1cc(Cl)cc(-c2cc(NC([C@@H](C3)CNC3=O)=O)n[n]2-c(cc2)ccc2F)c1 Chemical compound CC(C(F)(F)F)(C=C)OCc1cc(Cl)cc(-c2cc(NC([C@@H](C3)CNC3=O)=O)n[n]2-c(cc2)ccc2F)c1 SYMOGWFEUPBHHR-LFUZPPSTSA-N 0.000 description 1
- XIDPUBVYKRDFSH-ZCFIWIBFSA-N CC(C)(C)OC([C@@H](CN1)N(C)C1=O)=O Chemical compound CC(C)(C)OC([C@@H](CN1)N(C)C1=O)=O XIDPUBVYKRDFSH-ZCFIWIBFSA-N 0.000 description 1
- UXXMTTUPUBIXSH-NIVRMLGLSA-N CC([C@@H]([C@H]1C)[C@]1(C)NC)N Chemical compound CC([C@@H]([C@H]1C)[C@]1(C)NC)N UXXMTTUPUBIXSH-NIVRMLGLSA-N 0.000 description 1
- PMYVDZRJVDXBML-UHFFFAOYSA-N CC1(C)OB(c2cccc(COCC(F)(F)F)c2)OC1(C)C Chemical compound CC1(C)OB(c2cccc(COCC(F)(F)F)c2)OC1(C)C PMYVDZRJVDXBML-UHFFFAOYSA-N 0.000 description 1
- XZYVPSUPUXHPHU-UHFFFAOYSA-N CCC(C(CC(O)O)C(O)OC(F)(F)F)O Chemical compound CCC(C(CC(O)O)C(O)OC(F)(F)F)O XZYVPSUPUXHPHU-UHFFFAOYSA-N 0.000 description 1
- OZFGRQLUQFPWPR-UHFFFAOYSA-N COc1ccc(CN(CC(C2)C(O)=O)C2=O)c(OC)c1 Chemical compound COc1ccc(CN(CC(C2)C(O)=O)C2=O)c(OC)c1 OZFGRQLUQFPWPR-UHFFFAOYSA-N 0.000 description 1
- GFYYXHWCEPUTLM-XVMARJQXSA-N C[C@@H]([C@@H](C)N1)C2(CC2)[C@@H]1O Chemical compound C[C@@H]([C@@H](C)N1)C2(CC2)[C@@H]1O GFYYXHWCEPUTLM-XVMARJQXSA-N 0.000 description 1
- MNQLLBYNWQEUDQ-XPCCGILXSA-N C[C@H](C(F)(F)F)OCc1cc(-c2cc(NC(C(C3)CNC3=O)=O)n[n]2-c2ccccc2)cc(Cl)c1 Chemical compound C[C@H](C(F)(F)F)OCc1cc(-c2cc(NC(C(C3)CNC3=O)=O)n[n]2-c2ccccc2)cc(Cl)c1 MNQLLBYNWQEUDQ-XPCCGILXSA-N 0.000 description 1
- QJYBFKDHLUMYMI-SNVBAGLBSA-N C[C@H](C(F)(F)F)OCc1cc(B2OC(C)(C)C(C)(C)O2)cc(F)c1 Chemical compound C[C@H](C(F)(F)F)OCc1cc(B2OC(C)(C)C(C)(C)O2)cc(F)c1 QJYBFKDHLUMYMI-SNVBAGLBSA-N 0.000 description 1
- VZTHIUBPUTUJCD-SSDOTTSWSA-N C[C@H](C(F)(F)F)OCc1cc(F)ccc1 Chemical compound C[C@H](C(F)(F)F)OCc1cc(F)ccc1 VZTHIUBPUTUJCD-SSDOTTSWSA-N 0.000 description 1
- GHGXJLCPZUNBRR-GKOGFXNCSA-N C[C@H](C(F)(F)F)OCc1cccc(C2=CC(N)NN2c(cc2)ccc2Cl)c1 Chemical compound C[C@H](C(F)(F)F)OCc1cccc(C2=CC(N)NN2c(cc2)ccc2Cl)c1 GHGXJLCPZUNBRR-GKOGFXNCSA-N 0.000 description 1
- KVTPQQWGYTVBMR-UHFFFAOYSA-N Cc1cc(N)n[n]1-c(cc1)ccc1F Chemical compound Cc1cc(N)n[n]1-c(cc1)ccc1F KVTPQQWGYTVBMR-UHFFFAOYSA-N 0.000 description 1
- MHIXGDUPWXOWPY-UHFFFAOYSA-N FC(COCc1cc(F)ccc1)(F)F Chemical compound FC(COCc1cc(F)ccc1)(F)F MHIXGDUPWXOWPY-UHFFFAOYSA-N 0.000 description 1
- SCBZBMXPJYMXRC-UHFFFAOYSA-N Fc1cc(CBr)ccc1 Chemical compound Fc1cc(CBr)ccc1 SCBZBMXPJYMXRC-UHFFFAOYSA-N 0.000 description 1
- SJLJTBWRPMYKIO-WSLMLHKMSA-N N=C(/C=C(/c1cc(COCC(F)(F)F)ccc1)\Nc(cc1)ccc1F)NC([C@@H](C1)CNC1=O)=O Chemical compound N=C(/C=C(/c1cc(COCC(F)(F)F)ccc1)\Nc(cc1)ccc1F)NC([C@@H](C1)CNC1=O)=O SJLJTBWRPMYKIO-WSLMLHKMSA-N 0.000 description 1
- BNSGETUCOUAJJA-UHFFFAOYSA-N NC(C=C1c2cc(COCC(F)(F)F)cc(F)c2)NN1c(cc1)ccc1Cl Chemical compound NC(C=C1c2cc(COCC(F)(F)F)cc(F)c2)NN1c(cc1)ccc1Cl BNSGETUCOUAJJA-UHFFFAOYSA-N 0.000 description 1
- MCCRWOSCRUCJOF-UHFFFAOYSA-N NC(C=C1c2cc(COCC(F)(F)F)ccc2)NN1c(cc1)ccc1F Chemical compound NC(C=C1c2cc(COCC(F)(F)F)ccc2)NN1c(cc1)ccc1F MCCRWOSCRUCJOF-UHFFFAOYSA-N 0.000 description 1
- GGCMPAFGGWKMTI-INIZCTEOSA-N O=C(CNc(cc1-c2cc(COCC(F)(F)F)cc(F)c2)n[n]1-c(cc1)ccc1F)[C@@H](C1)CNC1=O Chemical compound O=C(CNc(cc1-c2cc(COCC(F)(F)F)cc(F)c2)n[n]1-c(cc1)ccc1F)[C@@H](C1)CNC1=O GGCMPAFGGWKMTI-INIZCTEOSA-N 0.000 description 1
- YICFEJGINLJYAU-OOJLDXBWSA-N O=C([C@@H](C1)CNC1=O)NC(C=C1c2cc(COCC(F)(F)F)cc(F)c2)NN1c(cc1)ccc1Cl Chemical compound O=C([C@@H](C1)CNC1=O)NC(C=C1c2cc(COCC(F)(F)F)cc(F)c2)NN1c(cc1)ccc1Cl YICFEJGINLJYAU-OOJLDXBWSA-N 0.000 description 1
- JJPJJXCBJHFTDE-INIZCTEOSA-N O=C([C@@H](C1)CNC1=O)Nc(cc1-c2cc(COCC(F)(F)F)ccc2)n[n]1-c(cc1)ccc1Cl Chemical compound O=C([C@@H](C1)CNC1=O)Nc(cc1-c2cc(COCC(F)(F)F)ccc2)n[n]1-c(cc1)ccc1Cl JJPJJXCBJHFTDE-INIZCTEOSA-N 0.000 description 1
- GZVHQYZRBCSHAI-UHFFFAOYSA-N OC(C(C1)CNC1=O)=O Chemical compound OC(C(C1)CNC1=O)=O GZVHQYZRBCSHAI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012190429A JP6091811B2 (ja) | 2011-08-31 | 2012-08-30 | ピラゾール化合物及びその医薬用途 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011188121 | 2011-08-31 | ||
| JP2011188121 | 2011-08-31 | ||
| JP2012190429A JP6091811B2 (ja) | 2011-08-31 | 2012-08-30 | ピラゾール化合物及びその医薬用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017021326A Division JP2017082005A (ja) | 2011-08-31 | 2017-02-08 | ピラゾール化合物及びその医薬用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013063968A JP2013063968A (ja) | 2013-04-11 |
| JP2013063968A5 JP2013063968A5 (enExample) | 2015-10-15 |
| JP6091811B2 true JP6091811B2 (ja) | 2017-03-08 |
Family
ID=47756400
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012190429A Active JP6091811B2 (ja) | 2011-08-31 | 2012-08-30 | ピラゾール化合物及びその医薬用途 |
| JP2017021326A Ceased JP2017082005A (ja) | 2011-08-31 | 2017-02-08 | ピラゾール化合物及びその医薬用途 |
| JP2018088578A Ceased JP2018115216A (ja) | 2011-08-31 | 2018-05-02 | ピラゾール化合物及びその医薬用途 |
| JP2020081097A Ceased JP2020125348A (ja) | 2011-08-31 | 2020-05-01 | ピラゾール化合物及びその医薬用途 |
| JP2023075967A Ceased JP2023087032A (ja) | 2011-08-31 | 2023-05-02 | ピラゾール化合物及びその医薬用途 |
| JP2025000092A Withdrawn JP2025039641A (ja) | 2011-08-31 | 2025-01-06 | ピラゾール化合物及びその医薬用途 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017021326A Ceased JP2017082005A (ja) | 2011-08-31 | 2017-02-08 | ピラゾール化合物及びその医薬用途 |
| JP2018088578A Ceased JP2018115216A (ja) | 2011-08-31 | 2018-05-02 | ピラゾール化合物及びその医薬用途 |
| JP2020081097A Ceased JP2020125348A (ja) | 2011-08-31 | 2020-05-01 | ピラゾール化合物及びその医薬用途 |
| JP2023075967A Ceased JP2023087032A (ja) | 2011-08-31 | 2023-05-02 | ピラゾール化合物及びその医薬用途 |
| JP2025000092A Withdrawn JP2025039641A (ja) | 2011-08-31 | 2025-01-06 | ピラゾール化合物及びその医薬用途 |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US8846746B2 (enExample) |
| EP (4) | EP3199533B1 (enExample) |
| JP (6) | JP6091811B2 (enExample) |
| KR (1) | KR101989203B1 (enExample) |
| CN (1) | CN103917535B (enExample) |
| AR (2) | AR087701A1 (enExample) |
| AU (1) | AU2012302723B2 (enExample) |
| BR (1) | BR112014004651B1 (enExample) |
| CA (1) | CA2845127C (enExample) |
| CL (1) | CL2014000490A1 (enExample) |
| CO (1) | CO6890098A2 (enExample) |
| CY (1) | CY1121631T1 (enExample) |
| DK (1) | DK3199533T3 (enExample) |
| HK (1) | HK1202290A1 (enExample) |
| IL (1) | IL230763A (enExample) |
| MX (1) | MX359825B (enExample) |
| MY (1) | MY172422A (enExample) |
| PE (1) | PE20142343A1 (enExample) |
| PH (1) | PH12014500444A1 (enExample) |
| PL (1) | PL3199533T3 (enExample) |
| RS (1) | RS58870B1 (enExample) |
| RU (1) | RU2617678C2 (enExample) |
| SG (1) | SG11201400244YA (enExample) |
| SI (1) | SI3199533T1 (enExample) |
| SM (1) | SMT201900292T1 (enExample) |
| TW (1) | TWI549949B (enExample) |
| WO (1) | WO2013031922A1 (enExample) |
| ZA (1) | ZA201401071B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017082005A (ja) * | 2011-08-31 | 2017-05-18 | 日本たばこ産業株式会社 | ピラゾール化合物及びその医薬用途 |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA117092C2 (uk) | 2011-09-06 | 2018-06-25 | Байєр Інтеллектуал Проперті Гмбх | Амінозаміщені імідазопіридазини |
| EP2848254B1 (en) | 2012-05-07 | 2016-08-03 | Kissei Pharmaceutical Co., Ltd. | Pyrazole derivative and use thereof for medical purposes |
| HK1208025A1 (en) | 2012-11-19 | 2016-02-19 | 拜耳医药股份公司 | Aminoimidazopyridazines |
| WO2014119787A1 (ja) * | 2013-02-04 | 2014-08-07 | 大正製薬株式会社 | 便秘症の予防又は治療薬 |
| WO2014182955A2 (en) * | 2013-05-08 | 2014-11-13 | The University Of Houston System | Targeting the egfr-sglt1 interaction for cancer therapy |
| CN105294703B (zh) * | 2015-10-23 | 2018-01-23 | 西安近代化学研究所 | 3,7,10‑三氧代‑2,4,6,8,9,11‑六氮杂[3,3,3]螺桨烷的合成方法 |
| CN109790150A (zh) | 2016-08-11 | 2019-05-21 | 拜耳作物科学股份公司 | 取代的吡唑啉基衍生物、其制备方法及其作为除草剂和/或植物生长调节剂的用途 |
| JP6994498B2 (ja) | 2016-08-15 | 2022-02-04 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | ３－アミノ－１－（２，６－二置換フェニル）ピラゾール類を調製する方法 |
| TWI805699B (zh) * | 2018-03-01 | 2023-06-21 | 日商日本煙草產業股份有限公司 | 甲基內醯胺環化合物及其用途 |
| AR114465A1 (es) * | 2018-04-04 | 2020-09-09 | Japan Tobacco Inc | Compuestos de pirazol sustituidos con heteroarilo y su utilización farmacéutica |
| KR20220057562A (ko) * | 2019-09-04 | 2022-05-09 | 니뽄 다바코 산교 가부시키가이샤 | 만성 신장병의 치료 또는 예방 방법 |
| WO2021045159A1 (ja) * | 2019-09-04 | 2021-03-11 | 日本たばこ産業株式会社 | 併用医薬による糖尿病の治療又は予防方法 |
| WO2021187548A1 (ja) | 2020-03-19 | 2021-09-23 | 日本たばこ産業株式会社 | 慢性心不全の治療又は予防方法 |
| WO2025249555A1 (en) * | 2024-05-31 | 2025-12-04 | Japan Tobacco Inc. | Method for treating or preventing hypertrophic cardiomyopathy |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2713225B1 (fr) | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
| WO2001012189A1 (en) * | 1999-08-12 | 2001-02-22 | Pharmacia Italia S.P.A. | 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| US6387900B1 (en) * | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
| US8084467B2 (en) * | 1999-10-18 | 2011-12-27 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
| US7375087B2 (en) * | 2002-08-08 | 2008-05-20 | Kissei Pharmaceutical Co., Ltd. | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
| JP2004137245A (ja) * | 2002-08-23 | 2004-05-13 | Kissei Pharmaceut Co Ltd | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
| US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| DE102004028241B4 (de) | 2004-06-11 | 2007-09-13 | Sanofi-Aventis Deutschland Gmbh | Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel |
| AR051446A1 (es) * | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
| AU2005308575A1 (en) | 2004-11-23 | 2006-06-01 | Warner-Lambert Company Llc | 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia |
| WO2007034279A2 (en) * | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | C3a antagonists and pharmaceutical compositions thereof |
| JP5069894B2 (ja) * | 2005-10-21 | 2012-11-07 | 田辺三菱製薬株式会社 | ピラゾール化合物 |
| WO2007046550A1 (en) | 2005-10-21 | 2007-04-26 | Mitsubishi Tanabe Pharma Corporation | Pyrazole compounds having cannabinoid receptor (cb1) antagonizing activity |
| TWI378922B (en) * | 2005-10-21 | 2012-12-11 | Mitsubishi Tanabe Pharma Corp | A pyrazole compound |
| US20070117858A1 (en) * | 2005-11-23 | 2007-05-24 | Mingde Xia | Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators |
| JP2010505957A (ja) * | 2006-10-10 | 2010-02-25 | アムゲン インコーポレイティッド | 糖尿病に対して使用されるｎ−アリールピラゾール化合物 |
| JP4994295B2 (ja) | 2007-04-20 | 2012-08-08 | 田辺三菱製薬株式会社 | 医薬組成物 |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| JP2010222298A (ja) * | 2009-03-24 | 2010-10-07 | Shionogi & Co Ltd | Ｎｐｙｙ５受容体拮抗作用を有するピロリドン誘導体 |
| US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| US8163704B2 (en) * | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| JP6155187B2 (ja) | 2010-03-30 | 2017-06-28 | ヴァーセオン コーポレイション | トロンビンの阻害剤としての多置換芳香族化合物 |
| CA2804225C (en) | 2010-07-02 | 2018-05-01 | Aska Pharmaceutical Co., Ltd. | Heterocyclic compound and p27kip1 degradation inhibitor |
| US20140031547A1 (en) | 2010-12-14 | 2014-01-30 | Electrophoretics Limited | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES |
| AR087701A1 (es) * | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
-
2012
- 2012-08-28 AR ARP120103173A patent/AR087701A1/es active IP Right Grant
- 2012-08-30 US US13/599,665 patent/US8846746B2/en active Active
- 2012-08-30 SI SI201231595T patent/SI3199533T1/sl unknown
- 2012-08-30 RU RU2014112048A patent/RU2617678C2/ru active
- 2012-08-30 EP EP17157922.0A patent/EP3199533B1/en active Active
- 2012-08-30 EP EP25203401.2A patent/EP4656638A3/en active Pending
- 2012-08-30 AU AU2012302723A patent/AU2012302723B2/en active Active
- 2012-08-30 PH PH1/2014/500444A patent/PH12014500444A1/en unknown
- 2012-08-30 RS RS20190581A patent/RS58870B1/sr unknown
- 2012-08-30 DK DK17157922.0T patent/DK3199533T3/da active
- 2012-08-30 MY MYPI2014000387A patent/MY172422A/en unknown
- 2012-08-30 CA CA2845127A patent/CA2845127C/en active Active
- 2012-08-30 HK HK15102725.1A patent/HK1202290A1/en unknown
- 2012-08-30 PE PE2014001489A patent/PE20142343A1/es active IP Right Grant
- 2012-08-30 JP JP2012190429A patent/JP6091811B2/ja active Active
- 2012-08-30 EP EP12827193.9A patent/EP2784074A4/en not_active Withdrawn
- 2012-08-30 TW TW101131507A patent/TWI549949B/zh active
- 2012-08-30 PL PL17157922T patent/PL3199533T3/pl unknown
- 2012-08-30 BR BR112014004651-4A patent/BR112014004651B1/pt active IP Right Grant
- 2012-08-30 MX MX2014002552A patent/MX359825B/es active IP Right Grant
- 2012-08-30 WO PCT/JP2012/072066 patent/WO2013031922A1/ja not_active Ceased
- 2012-08-30 CN CN201280050398.9A patent/CN103917535B/zh active Active
- 2012-08-30 SM SM20190292T patent/SMT201900292T1/it unknown
- 2012-08-30 EP EP19159289.8A patent/EP3524599A1/en not_active Withdrawn
- 2012-08-30 KR KR1020147004780A patent/KR101989203B1/ko active Active
- 2012-08-30 SG SG11201400244YA patent/SG11201400244YA/en unknown
-
2014
- 2014-02-02 IL IL230763A patent/IL230763A/en active IP Right Grant
- 2014-02-11 ZA ZA2014/01071A patent/ZA201401071B/en unknown
- 2014-02-25 CO CO14038962A patent/CO6890098A2/es active IP Right Grant
- 2014-02-27 CL CL2014000490A patent/CL2014000490A1/es unknown
- 2014-07-29 US US14/445,500 patent/US20150183763A1/en not_active Abandoned
-
2017
- 2017-02-08 JP JP2017021326A patent/JP2017082005A/ja not_active Ceased
- 2017-12-21 US US15/850,874 patent/US20180346449A1/en not_active Abandoned
-
2018
- 2018-05-02 JP JP2018088578A patent/JP2018115216A/ja not_active Ceased
-
2019
- 2019-05-08 CY CY20191100491T patent/CY1121631T1/el unknown
- 2019-11-07 US US16/677,523 patent/US20200317644A1/en not_active Abandoned
-
2020
- 2020-05-01 JP JP2020081097A patent/JP2020125348A/ja not_active Ceased
-
2021
- 2021-09-06 AR ARP210102479A patent/AR123441A2/es unknown
-
2022
- 2022-12-02 US US18/061,309 patent/US20230348438A1/en active Pending
-
2023
- 2023-05-02 JP JP2023075967A patent/JP2023087032A/ja not_active Ceased
-
2025
- 2025-01-06 JP JP2025000092A patent/JP2025039641A/ja not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017082005A (ja) * | 2011-08-31 | 2017-05-18 | 日本たばこ産業株式会社 | ピラゾール化合物及びその医薬用途 |
| JP2018115216A (ja) * | 2011-08-31 | 2018-07-26 | 日本たばこ産業株式会社 | ピラゾール化合物及びその医薬用途 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023087032A (ja) | ピラゾール化合物及びその医薬用途 | |
| KR101088247B1 (ko) | 크로메인 치환된 벤즈이미다졸 및 이들의 산 펌프억제제로서의 용도 | |
| CN101309917B (zh) | 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂 | |
| EA021126B1 (ru) | Замещенные изохинолиноны и хинализолиноны | |
| CN102341395A (zh) | 作为抗炎剂的3H-咪唑并[4，5-c]吡啶-6-甲酰胺 | |
| TWI439452B (zh) | 吡咯烷化合物（二） | |
| EP1724259A1 (en) | 2,7-substituted 5-amino-4-hydroxy-8-(1h-indazol-5-yl)-octan amide derivatives and related compounds as renin inhibitors for the treatment of hypertension | |
| KR101378260B1 (ko) | 세로토닌 및 노르에피네프린 재흡수 억제제 | |
| HK1242309A1 (en) | Pyrazole compound and pharmaceutical use thereof | |
| HK1242309B (en) | Pyrazole compound and pharmaceutical use thereof | |
| NZ620977B2 (en) | Pyrazole compound and use thereof for medical purposes | |
| AU2018211735A1 (en) | Phenyldifluoromethyl-substituted prolinamide compound | |
| CN106496132A (zh) | N‑(4‑取代苯基)‑2‑取代乙酰胺类化合物及其作为sirt2蛋白抑制剂的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150828 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150828 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20160219 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160623 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160726 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160912 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170110 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170208 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6091811 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |